Medidata has unveiled its enhanced, Artificial Intelligence (AI)-powered imaging solution, within the Medidata Data Experience—which connects every stage of the clinical data lifecycle—at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. By integrating established AI with direct feedback from clinical study teams, this re-engineered capability shatters traditional imaging bottlenecks, delivering a new standard of unmatched accuracy and speed—critical for breakthroughs in oncology and other therapeutic areas.

Medidata Imaging is built on proprietary algorithms engineered to deliver immediate, measurable impact to trials by solving major pain points in oncology and other image-dependent studies, including 32 percent faster protected health information redaction (an automated text detection algorithm eliminates the need for manual redaction); greater than 97 percent accuracy (AI-powered algorithms deliver anatomy verification with considerably greater accuracy than industry benchmarks); and quality control results in minutes (Medidata Imaging will also soon include intelligent ‘patient similarity’ quality control checks that validate patient identity, the presence of IV/oral contrast, and proper field of view, delivering nearly immediate, actionable feedback to rapidly address imaging issues and avoid costly delays.

Wayne Walker, Senior Vice President, Data Experience, Medidata, said, "At Medidata, we are embedding AI as a foundational element, bringing intelligence to every stage of the clinical journey—and Medidata Imaging is a critical component of that evolution. In oncology, where tumor progression serves as the primary endpoint in over 90 percent of trials, imaging provides the pivotal, objective proof required to determine a treatment's efficacy and deliver hope to patients. By infusing AI further into the data experience, we are delivering the transformative power of unprecedented accuracy and speed, directly accelerating clinical breakthroughs that lead to better patient outcomes."

The complexity of modern clinical trials, especially for cancer therapies, requires a continuous evolution in clinical research technology. Building on its strong foundation—which supported more than 95 percent of all oncology drug approvals in 2025 and was preferred two-to-one by clinical trial sites—Medidata is continuing to invest in cutting-edge imaging capabilities to further advance oncology trials.

Targeted for launch next year, this suite of capabilities will feature, among other advancements, a specialist interface and one-click image transfers that leverage Medidata’s existing network of over 1,000 US hospitals. Taken together, these advancements will be another significant leap forward in connecting clinical sites with the speed of AI-driven innovation.